Real-world characteristics and outcomes of patients with BRAF^V600E-mutant metastatic colorectal cancer in Australia: the COALA project.

ABSTRACT:

Background

BRAF^V600E-mutated metastatic colorectal cancer (mCRC) is a biologically distinct and clinically aggressive subtype associated with poor outcomes. Real-world data on this population remains limited, particularly within the Australian health care setting.

Patients and methods

The COALA study is a national, prospective registry-based observational analysis of patients with mCRC across 21 Australian institutions. Data were extracted from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) and TRACC-Select registries and included demographics, molecular profiles, treatment patterns and overall survival (OS). Uptake and impact of encorafenib plus cetuximab (EC), since being available in Australia from May 2019, were examined.

Results

Of 2

SUBMITTER: Hitchen N 

PROVIDER: S-EPMC12836788 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature